O'Mahony Deirdre, Kummar Shivaani, Gutierrez Martin E
Medical Oncology Clinical Research Unit, Center for Cancer Research, 10 Center Dr, Building 10, Room 12N226, Bethesda, MD 20892-1906, USA.
J Clin Oncol. 2005 Dec 10;23(35):9022-8. doi: 10.1200/JCO.2005.02.3101. Epub 2005 Oct 11.
Lung cancer is the leading cause of cancer deaths in the United States and throughout the world; globally, there are more than 1.1 million deaths each year. Treatment modalities currently employed are significantly limited; 50% of patients experience disease recurrence after surgery, and less than a quarter of patients respond to systemic chemotherapy. These statistics have fueled the search for a safer, more effective treatment modality. Despite significant advances in our understanding of the molecular basis of cancer immunology, many obstacles remain. However, encouraging clinical results in patients immunized with autologous tumor cell vaccines expressing granulocyte macrophage colony-stimulating factor strongly advocate further investigation of immunotherapy in non-small-cell lung cancer (NSCLC). Further studies are needed to demonstrate whether these novel therapies can potentially complement or even replace current therapeutic approaches. We present a review of the various vaccine-based strategies employed to target and treat NSCLC.
肺癌是美国乃至全世界癌症死亡的主要原因；在全球范围内，每年有超过110万人死于肺癌。目前采用的治疗方式极为有限；50%的患者术后会出现疾病复发，且不到四分之一的患者对全身化疗有反应。这些统计数据推动了人们对更安全、更有效治疗方式的探索。尽管我们对癌症免疫学的分子基础有了重大进展，但仍存在许多障碍。然而，用表达粒细胞巨噬细胞集落刺激因子的自体肿瘤细胞疫苗免疫的患者取得了令人鼓舞的临床结果，这有力地支持了在非小细胞肺癌（NSCLC）中进一步研究免疫疗法。还需要进一步研究来证明这些新疗法是否有可能补充甚至取代当前的治疗方法。我们对用于靶向和治疗NSCLC的各种基于疫苗的策略进行了综述。
